2 results
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.
Approved WMORecruiting
The primary objective of this study is to assess the number of detected pheochromocytoma lesions, proved by histology, with [18F]mFBG PET-CT compared to the conventional CT.